MANKIND — Mankind Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Mankind Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	C2022 March 31st	2023 March 31st	R2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	PRESS	PRESS
Standards:	IAS	IAS	IAS	—	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	62,144	77,816	87,494	102,604	122,074
Cost of Revenue
Gross Profit	43,069	52,084	56,781	70,620	87,184
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	46,823	59,296	71,747	81,252	98,107
Operating Profit	15,322	18,520	15,747	21,353	23,967
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	16,916	19,746	16,712	23,979	25,163
Provision for Income Taxes
Net Income After Taxes	12,930	14,530	13,097	19,408	20,066
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	12,654	14,335	12,819	19,129	19,910
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	12,654	14,335	12,819	19,129	19,910
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	32	35.4	32.1	47.7	49.1